General description

The objectives of the European Scientific foundation for Laboratory Hemato Oncology (ESLHO) are:

1. To promote the continuous innovation and standardization of laboratory diagnostics focused on lymphoid malignancies;
2. Quality control and education of laboratory diagnostics focused on lymphoid malignancies.

ESLHO aims to realize its objectives by:

1. Supporting the organization and the contents of the programs of scientific meetings for the design, standardization and clinical validation of innovative tools and technologies for diagnostic patient care;
2. Organizing quality control rounds for which a certificate of participation and performance will be provided;
3. Organizing educational sessions for which ESLHO aims to acquire Continuing Medical Education (CME) accreditation;
4. Promoting Good Laboratory Practice by promoting the use of standardized protocols.

Three scientific European Consortia operate under the umbrella of ESLHO:

1. EuroFlow (www.euroflow.org)
2. EuroMRD (www.euromrd.org)
3. EuroClonality (www.euroclonality.org)

Composition of ESLHO Board

Prof. Dr J.J.M. van Dongen, LUMC, Leiden, NL (Chair)
Dr. J. Hancock, Southmead Hospital, Bristol, UK (Treasurer)
Dr. T. Raff, University Hospital Schleswig-Holstein, Kiel, DE (Secretary)
Prof. Dr. A. Orfao, University of Salamanca, Salamanca, ES
Dr. P.J.T.A. Groenen, Radboud UMC, Nijmegen, NL
Prof. Dr. B. Schäfer, University Children’s Hospital, Zurich, CH
W.M. Comans-Bitter (office management)
Conflicts of interest of ESLHO Foundation

The Board members have no conflict of interest other than the fact that the EuroFlow and EuroClonality Consortia own patents, which are licensed to industry and which provide revenues (royalties) to the Consortia. These revenues are for 100% being used to continue the collaboration within the Consortia by financially supporting meetings, quality assessment programs, special needs for reagents and tools for collaborative projects, and office management.

List of ESLHO activities

- 10th ESLHO Board meeting, Copenhagen, DK (9 June 2016)
- 11th ESLHO Board meeting, TC, CH (26 October 2016)
- 5th ESLHO Symposium: New developments in the ESLHO Networks, Prague, CZ (3 November 2016) (158 participants from 22 countries)

List of ESLHO publications (last 4 years)


For more information: www.eslho.org

The EuroFlow consortium consists of 23 diagnostic research groups from 11 countries and one associated SME, which are regarded as experts in the fields of flow cytometric and molecular diagnostics. Together the participants have sufficient complementarily and congruence to cover all aspects of development, standardization, and validation of highly sensitive tests for diagnosis and follow-up. The EuroFlow Consortium was initiated with support of the European Commission as Specific Targeted research Project in the 6th framework programme (LSHB-CT-2006-018708).

The main objective of the EuroFlow Consortium is the development and standardization of fast, accurate, and highly sensitive flow cytometric tests for diagnosis and prognostic (sub) classification of hematological malignancies as well as for evaluation of treatment effectiveness during follow-up. This includes the introduction of novel flow cytometric methods for replacing several types of molecular techniques (particularly PCR-based detection of fusion genes and oncogenes).
Based on the acquired experience, the EuroFlow Consortium has aimed to translate their knowledge and technology to applications in flow cytometric diagnostics of primary immunodeficiencies. A special PID Workpackage was formed within EuroFlow, with the aim to design special 8-color tubes for the assessment of all relevant B-cell and T-cell subsets in blood and the precursor-B cell compartment in bone marrow.

**Chair of EuroFlow**

Prof. Dr. J.J.M. van Dongen, LUMC, Leiden, NL  
Prof. Dr. A. Orfao, University of Salamanca, Salamanca, ES (co-chair)

**Composition of the EuroFlow Board**

Prof. dr J.J.M. van Dongen, LUMC, Leiden, NL (Chair)  
Prof. Dr. A. Orfao, University of Salamanca, Salamanca, ES (Co-chair)  
W.M. Bitter, LUMC, Leiden, NL (Treasurer)  
Dr. S. Böttcher, University of Schleswig-Holstein, Kiel, DE  
Dr. T. Kalina, Charles University, Prague, CZ  
Prof. Dr. M. Lima, University of Porto, Porto, PT  
Prof. Dr. E. Macintyre, Hôpital Necker-Enfants Malades, Paris, FR  
Dr. A. Medina Almeida, Instituto Português de Oncologia, Lisbon, PT  
Prof. Dr. C.E. Pedreira, Federal University of Rio de Janeiro, Rio de Janeiro, BR  
Dr. E. Sonneveld, Dutch Childhood Oncology Group, The Hague, NL  
Prof. Dr. T. Szczepanskí, Medical University of Silesia, Zabrze, PL  
Dr. V.H.J. van der Velden, Erasmus MC, Rotterdam, NL

**Conflicts of interest of the EuroFlow Consortium**

The EuroFlow Consortium has filed patents concerning novel technologies and novel results. These patents are collectively owned and the revenues are exclusively used for Consortium activities.

The Board members have no conflict of interest.

**EuroFlow Membership list** (contact person of each participating institute)

Leiden, NL: Prof. Dr. J.J.M. van Dongen, jj.m.van_dongen@lumc.nl  
Rotterdam, NL: Dr. V.H.J. van der Velden, v.h.j.vandervelden@erasmusmc.nl  
Rotterdam, NL: Dr. A.W. Langerak, a.w.langerak@erasmusmc.nl  
Rotterdam, NL: Dr. M. van der Burg, m.vanderburg@erasmusmc.nl  
Salamanca, ES: Prof. Dr. A. Orfao, orfao@usal.es  
Salamanca, ES: Dr. J. Almeida, jalmeida@usal.es  
Salamanca, ES: Dr. J. Flores-Montero, jflores@usal.es  
Salamanca, ES: Dr. M. Pérez-Andres, mmar@usal.es  
Lisbon, PT: Dr. A. Medina Almeida, amalmeida@ipolisboa.min-saude.pt
List of EuroFlow activities

- Spanish EuroFlow Workshop, Madrid, ES (18-19 February 2016)
- 13th EuroFlow PID meeting in Rome, IT (8-9 March 2016)
- 28th EuroFlow meeting in Rome, IT (9-11 March 2016)
- 17th EuroFlow Board meeting, Rome, IT (9 March 2016)
- 2nd Italian EuroFlow Workshop, Rome, IT (11-12 March 2016)
- Mexican EuroFlow Workshop, Mexico City, Mexico (17-18 March 2016)
- Austrian EuroFlow Workshop, Vienna, AT (14-15 April 2016)
- 14th EuroFlow PID meeting, Leiden, NL (28-29 June 2016)
- 1st EuroFlow-PERISCOPE Educational & Training meeting, Leiden, NL (30 June – 1 July 2016)
- EuroFlow Workshop in Cusco, Peru (24-26 August 2016)
- 2nd EuroFlow-PERISCOPE Educational & Training meeting, Salamanca, ES (21-22 September 2016)
- 2nd Canadian EuroFlow Workshop, Vancouver, CA (29-30 September 2016)
- 2nd International IMF-EuroFlow workshop on MM MRD, Salamanca, ES (10-11 October 2016)
- 15th EuroFlow PID meeting in Prague, CZ (31 October – 1 November 2016)
- 29th EuroFlow meeting in Prague, CZ (1-3 November 2016)
- 18th EuroFlow Board meeting, Prague, CZ (1 November 2016)
• 3rd EuroFlow-PERISCOPE Educational & Training meeting, Leiden, NL (17-18 November 2016)
• EuroFlow Workshop: Contributo da Citometria no diagnóstico de doenças múltiplas vs heterogeneidade clonal, Coimbra, PT (21-22 November 2016)
• 1st EuroFlow QA Educational meeting, Aarau, CH (23 November 2016)
• 2nd Swiss EuroFlow Workshop, Aarau, CH (24-25 November 2016)

List of EuroFlow publications (last 2 years)


---

### EuroMRD

The EuroMRD Consortium was established in 2001 (formerly known as European Study Group on MRD detection in ALL; ESG-MRD-ALL) and consists of 58 MRD-PCR laboratories across 24 countries in Europe, Israel, Singapore, Japan, South America India and Australia.

The technical strategies developed in the EU-supported BIOMED-1 Concerted Action: "International standardization and evaluation of techniques for the detection of MRD in acute non-lymphocytic leukemia" (EU-DGXII grant: BMH1-CT94-1675) and in the International BFM Study Group (I-BFM-SG) formed the basis of the EuroMRD network.

The main aims of EuroMRD are:

1. Organisation of a quality-control program twice per year (ALL section, Lymphoma section; Interfant section and Ph+ALL section;
2. Collaborative development and evaluation of new MRD strategies and techniques;
4. Continuing medical education in the format of a one hour educational session (3 lectures), and with small group discussions on the results of the QC round.

**Chair of EuroMRD**

Prof. Dr. B.W. Schäfer, University Children’s Hospital, Zürich, CH

**Composition of the EuroMRD Board**

Prof. Dr. B.W. Schäfer, University Children’s Hospital, Zürich, CH (chair)
Dr. T. Raff, University Hospital Schleswig-Holstein, Kiel, DE (secretary)
Dr. J. Hancock, Southmead Hospital, Bristol, UK (treasurer)
Prof. Dr. J.J.M. van Dongen, LUMC, Rotterdam, NL (founding chairman 2002 – 2016)
Dr. J.-M. Cayuela, Hopital Saint Louis, Paris, FR
Dr. G. Cazzaniga, Università Milano-Bicocca, Monza, IT
Dr. C. Eckert, Charité CVK, Berlin, DE
Dr. R. Panzer-Grümayer, St. Anna Kinderspital, Vienna, AT
Dr. H. Pfeifer, Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt, DE
Dr. V.H.J. van der Velden, Erasmus MC, Rotterdam, NL
W.M. Bitter, Erasmus MC, Rotterdam, NL (Office management)

Conflicts of interest of the EuroMRD Board

The Board members have no conflict of interest.

EuroMRD Membership list (contact person of each participating institute)

Rotterdam, NL: Dr. V.H.J. van der Velden, v.h.j.vandervelden@erasmusmc.nl
Amsterdam, NL: Christa Homburg, c.homburg@sanquin.nl
Leiden, NL: Prof. Dr. J.J.M. van Dongen, j.j.m.van_dongen@lumc.nl
Bristol, UK: Dr. J. Hancock, Jeremy.hancock@nbt.nhs.uk
Sheffield, UK: J. Blackburn, james.blackburn@sch.nhs.uk
Glasgow, UK: Dr. S. Chudleigh, Sandra.chudleigh@ggc.scot.nhs.uk
London, UK: S. Bevan, shaun.bevan@bartsandthelondon.nhs.uk
London, UK: Dr. G. Gerrard, g.gerrard@imperial.ac.uk
London, UK: Dr. A. Fielding, a.fielding@ucl.ac.uk
Birmingham, UK: Dr. S. Akiki, susanna.akiki@bwhct.nhs.uk
Heidelberg, DE: Dr. R. Koehler, rolf_koehler@med.uni-heidelberg.de
Kiel, DE: Dr. J. Alten, julia.alten@padiatrics.uni-kiel.de
Kiel, DE: Prof. M. Kneba, sekretariat@med2.uni-kiel.de
Frankfurt, DE: Dr. H. Kreyenberg, Hermann.kreyenberg@kgu.de
Berlin, DE: Dr. C. Eckert, cornelia.eckert@charite.de
Hamburg, DE: Dr. U. Zur Stadt, zurstadt@uke.uni-hamburg.de
Paris, FR: Prof. Dr. E. Macintyre, elizabeth.macintyre@nck.aphp.fr
Paris, FR: Dr. J.M. Cayuela, jean-michel.cayuela@sls.aphp.fr
Paris, FR: Dr. H. Cavé, helene.cave@rdb.aphp.fr
Lille, FR: Dr. N. Grardel, Nathalie.grardel@chru-lille.fr
Creteil, FR: Prof. Dr. M.-H. Delfau-Larue, marie-helene.delfau@hmn.aphp.fr
Rennes, FR: Dr. M.L. Boulland, marielaure.boulland@chu-rennes.fr
Toulouse, FR: Prof. Dr. E. Delabesse, delabesse.e@chu-toulouse.fr
Grenoble, FR: Dr. M. Callanan, mary.callanan@ujf-grenoble.fr
Lyon, FR: Dr. S. Hayette, sandrine.hayette@chu-lyon.fr
Monza, IT: Dr. G. Cazzaniga, gianni.cazzaniga@hsgerardo.org
Padova, IT: Dr. M. Paganini, maddalena.paganini@unipd.it
Torino, IT: Dr. M. Ladetto, marco.ladetto@unito.it
Bergamo, IT: Dr. O. Spinelli, ospinelli@ospedalirioniti.bergamo.it
Roma, IT: Dr. L. Elia, elia@bce.uniroma1.it
Palermo, IT: Dr. A. Santoro, santoro.al@libero.it
Naples, IT: Dr. G. Muccioli Casadei, muccioli@dbbm.unina.it
Bologna, IT: Dr. I. Lacobucci, ilaria.lacobucci@unibo.it
Annual report SWG ESLHO 2016

Vienna, AT: Prof. Dr. E.R. Panzer, renate.panzer@ccri.at
Linz, AT: Dr. O. Zach, otto.zach@elisabethinen.or.at
Prague, CZ: Dr. J. Trka, jan.trka@lfmotol.cuni.cz
Brno, CZ: Dr. D. Dvorakova, ddvorak@fbrno.cz
Brussel, BE: Dr. M. Bakkus, marleen.bakkus@uzbrussel.be
Salmanca, ES: Dr. R. García Sanz, rgarcias@usal.es
Copenhagen, DK: Dr. H.O. Madsen, hom@rh.dk
Zürich, CH: Dr. S. Kubetzko, Susanne.kubetzko@kispi.uzh.ch
Sydney, AU: Dr. R. Sutton, rsutton@ccia.unsw.edu.au
Petah Tikva, IS: Dr. S. Avigad, savigad@post.tau.ac.il
Singapore, SG: Prof. Dr. A. Yeoh Eng Juh, allen.yeoh@nus.edu.sg
Lisbon, PT: Dr. P. Gameiro, pqgameiro@ipoisboa.min-saude.pt
Turku, FI: Dr. V. Juvonen, vesa.juvonen@tyks.fi
Oslo, NO: Dr. A. Tierens, anne.tierens@oslo-universitetssykehus.no
Nagakute, JP: Dr. T. Hori, hori@aichi-med-u.ac.jp
Nagoya, JP: Dr. Y. Yamashita, kujirayuca@gmail.com
Columbus, USA: Dr. J.M. Gastier-Foster, julie.gastier-foster@nationwidechildrens.org
Thessaloniki, GR: Dr. T. Touloumenidou, tasoula.t2002@yahoo.de
Krakow, PL: Dr. S. Czekalska, sczekalska@gmail.com
Warsaw, PL: Dr. K. Borg, kborg@ihih.waw.pl
Sao Paulo, BR: Dr. I. Bendit, isbendit@usp.br
Rio de Janeiro, BR: Dr. T. Renault Zalcberg, zalcberg@inca.gov.br
Buenos Aires, AR: Dr. C.N. Alonso, crisalon9@yahoo.com.ar
Kolkata, IN: Prof. V. Saha, vaskar.saha@tmckolkata.com

List of EuroMRD activities

- 29th ALL-QC round (spring 2016)
- 29th Lymphoma QC round (spring 2016)
- 17th Interfant-06 QC round (spring 2016)
- 17th Ph+ALL QC round (spring 2016)
- 30th ALL-QC round (autumn 2016)
- 30th Lymphoma QC round (autumn 2016)
- 18th Interfant-06 QC round (autumn 2016)
- 18th Ph+ALL QC round (autumn 2016)
- 25th EuroMRD meeting in Prague, CZ (4-5 November 2016)
- 18th EuroMRD Board meeting, Prague, CZ (4 November 2016)

List of EuroMRD publications (last 2 years)

- Kotrova AM, van der Velden VHJ, van Dongen JJM, Formankova R, Sedlacek P, Brüggemann M, Zuna J, Stary J, Trka J, Fronkova E. Amplicon NGS-based MRD after stem cell transplantation (SCT) is more specific for relapse prediction than qPCR and suggests the possibility of false-positive qPCR results. 5th ESLHO Symposium abstract book 2016: 76-77.

EuroClonality

EuroClonality is the name of a European consortium for the development of novel PCR-based methods that allow detection of gene rearrangements, particularly immunoglobulin (IG) and T-cell receptor (TCR) gene rearrangements, to be used for discrimination between normal (polyclonal) and abnormal/ malignant (monoclonal) lymphoproliferations in order to support the accurate and reliable diagnosis and follow-up of hematologic malignancies, particularly lymphoid malignancies. This particularly concerns the development, standardization and clinical evaluation of novel PCR primers and combinations of multiple PCR primers (multiplex PCR tubes) for detection of the different types of IG/TCR gene rearrangements as well as the design of novel methods for fast and automated analysis of the obtained PCR products in order to assess whether the obtained PCR products are diverse (polyclonal) or whether they are at least in part identical, corresponding with normal (polyclonal) lymphocytes or abnormal/malignant (monoclonal) lymphocytes, respectively.

The EuroClonality Consortium started via the BIOMED-2 Concerted Action BMH4-CT98-3936.

The EuroClonality group supports and advises other diagnostic laboratories in their diagnostic work on the diagnosis and follow-up of patients with hematological malignancies, as performed with the above described PCR methods. The support is given by a panel of experts via the EuroClonality website.

Chair of EuroClonality

Dr P. Groenen, Nijmegen, NL

Composition of the EuroClonality Board
Dr. P. Groenen, Nijmegen, NL (Chair)
Dr. A.W. Langerak, Rotterdam, NL (Treasurer)
Prof. Dr. J.J.M. van Dongen, LUMC, Leiden, NL (founding chairman 1999-2011)
Prof. Dr. M. Brüggemann, Kiel, DE
Dr. F. Davi, Paris, FR
Dr. J. Cabeçadas, Lisbon, PT
Dr. E. Moreau, Roeselare, BE

Conflicts of interest of the EuroClonality Board

The EuroClonality Consortium has filed patents concerning novel technologies and novel results. These patents are collectively owned and the revenues are exclusively used for Consortium activities.

The Board members have no conflict of interest.

EuroClonality Membership list (contact person of each participating institute)

Rotterdam, NL: Dr. A.W. Langerak (a.langerak@erasmusmc.nl)
Groningen, NL: Prof. Dr. E. Schuuring (e.schuuring@path.umcg.nl)
Nijmegen, NL: Dr. P.J.T.A. Groenen (patricia.groenen@radboudumc.nl)
Amsterdam, NL: Dr. M. Spaargaren (marcel.spaargaren@amc.uva.nl)
Leiden, NL: Prof. Dr. J.J.M. van Dongen (j.j.m.van_dongen@lumc.nl)
Roeselare, BE: Dr. E. Boone (eboone@azdelta.be)
Salamanca, ES: Dr. R. García Sanz (rgarcias@usal.es)
Madrid, ES: Dr. L. Lombardia (lombardia@cnio.es)
Santander, ES: Dr. S. Montes Moreno (smontes@humv.es)
Lisbon, PT: Dr. P. Gameiro (pgameiro@ipolisboa.min-saude.pt)
Lisbon, PT: Dr. J.M. Cabecadas (jcabecadas@ipolisboa.min-saude.pt)
Siena, IT: Dr. C. Bellan (Cristiana.bellan@unisi.it)
Torino, IT: Dr. F. di Celle (pfanciadielle@molinette.piemonte.it)
Southampton, UK: Dr. E. Hodges (Elizabeth.hodges@uhs.nhs.uk)
Belfast, UK: Dr. M. Catherwood (mark.catherwood@belfasttrust.hscni.net)
Cardiff, UK: Dr. S. Austin (Austinsj@cf.ac.uk)
Leeds, UK: Dr. P.A. Evans (paulevans@nhs.net)
Sutton, UK: Dr. D. Gonzalez de Castro (davidg@icr.ac.uk)
Cambridge, UK: Dr. H. Liu (hli291@cam.ac.uk)
Nottingham, UK: Dr. I. Carter (ian.carter@nuh.nhs.uk)
Aberdeen, UK: Dr. B.J. Milner (b.j.milner@abdn.ac.uk)
Kiel, DE: Dr. M. Brüggemann (m.brueggemann@med2.uni-kiel.de)
Kiel, DE: Prof. Dr. W. Klapper (wklapper@path.uni-kiel.de)
Berlin, DE: Prof. Dr. M. Hummel (michael.hummel@charile.de)
Tuebingen, DE: Prof. Dr. F. Fend (falko.fend@med.uni-tuebingen.de)
Paris, FR: Prof. Dr. E. Macintyre (Elizabetht.macintyre@nck.aphp.fr)
Paris, FR: Prof. Dr. F. Davi (fred.davi@psl.aphp.fr)
List of EuroClonality activities

- 17th EuroClonality/BIOMED-2 Educational Workshop on Clonality Assessment, Nijmegen, NL (15-17 February 2016)
- 21st EuroClonality Board meeting, Telephone Conference, 8 March 2016
- 11th EuroClonality-NGS meeting, Kiel, DE (13-15 April 2016)
- 22nd EuroClonality Board meeting, Telephone Conference, 21 April 2016
- 23rd EuroClonality Board meeting, Telephone Conference, 31 May 2016
- SWG session at 21st Congress of EHA: High throughput sequencing (HTS) of immunoglobulin (IG) and T-cell receptor (TR) genes in Hemato-Oncology (9 June 2016)
- EQA QA round/13th EuroClonality QA round (autumn 2016)
- 12th EuroClonality-NGS meeting, Thessaloniki, GR (3-5 October 2016)
- 24th EuroClonality Board meeting, Telephone Conference, 13 October 2016
- 29th EuroClonality meeting in Prague, CZ (2-3 November 2016)
- 25th EuroClonality Board meeting, Prague, CZ (2 November 2016)

List of EuroClonality publications (last 3 years)


